Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily S&P 500 Bull 3X Shares vs Tilray Brands Inc — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $297.97 (market cap $7.36B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Direxion Daily S&P 500 Bull 3X Shares is far larger — about 13.9× Tilray Brands Inc's market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily S&P 500 Bull 3X Shares for 32 Days and Tilray Brands Inc for 31 Days on average.
| SPXL | TLRY | |
|---|---|---|
Market Cap | $7.36B | $530.54M |
Volume | 1,835,467 | 9,099,075 |
Sector | Leveraged / Inverse | Health |
52-Week High | $301.38 | $21.00 |
52-Week Low | $170.20 | $3.57 |
Typical Hold Time | 32 Days | 31 Days |
Enterprise Value | — | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPXL, a leveraged ETF tracking the S&P 500, trades at $293.05, down 1.28% on the day. Technical indicators show a bullish trend with strong moving average support, though oscillators remain neutral. The ETF reflects broader market sentiment where S&P 500 earnings are expected to grow 35% in 2026 (24/7 Wall Street, 2026-10-03), yet concerns about profit growth slowing to 15% in 2027 and high concentration in top holdings create uncertainty.
The outlook for SPXL is tied to S&P 500 performance, with Wall Street projecting a 21% rise to 9,275 by September 2027 (The Motley Fool, 2026-09-30). Key risks include market volatility, geopolitical tensions, and slowing earnings growth. Opportunities lie in seasonal bullish trends and AI-driven corporate spending, but leveraged exposure amplifies both gains and losses.
Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.
TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
